Three Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 RESPONSE

被引：2
|
作者：
Lennox, Jeffrey L. [1 ]
Landovitz, Raphael J. [2 ]
Ribaudo, Heather J. [3 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[2] Univ Calif Los Angeles, Ctr Clin AIDS Res & Educ, Los Angeles, CA USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 162卷 / 06期
关键词：
D O I：
10.7326/L15-5066-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：461 / 462
页数：2
相关论文
共 50 条
  • [1] Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
    不详
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 161 (07) : I - 22
  • [2] Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
    Lennox, Jeffrey L.
    Landovitz, Raphael J.
    Ribaudo, Heather J.
    Ofotokun, Ighovwerha
    Na, Lumine H.
    Godfrey, Catherine
    Kuritzkes, Daniel R.
    Sagar, Manish
    Brown, Todd T.
    Cohn, Susan E.
    McComsey, Grace A.
    Aweeka, Francesca
    Fichtenbaum, Carl J.
    Presti, Rachel M.
    Koletar, Susan L.
    Haas, David W.
    Patterson, Kristine B.
    Benson, Constance A.
    Baugh, Bryan P.
    Leavitt, Randi Y.
    Rooney, James F.
    Seekins, Daniel
    Currier, Judith S.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 161 (07) : 461 - +
  • [3] Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 (vol 161, pg 461, 2014)
    Lennox, J. L.
    Landovitz, R. J.
    Ribaudo, H. J.
    Ofotokun, I
    Na, L. H.
    Godfrey, C.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 161 (07)
  • [4] Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. A randomized, controlled equivalence trial (vol 161, pg 461, 2014)
    Lennox, J. L.
    Landovitz, R. J.
    Ribaudo, H. J.
    Ofotokun, I
    Na, L. H.
    Godfrey, C.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 161 (09) : 680 - 680
  • [5] Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
    Haubrich, Richard H.
    Riddler, Sharon A.
    Ribaudo, Heather
    DiRenzo, Gregory
    Klingman, Karin L.
    Garren, Kevin W.
    Butcher, David L.
    Rooney, James F.
    Havlir, Diane V.
    Mellors, John W.
    [J]. AIDS, 2011, 25 (18) : 2269 - 2278
  • [6] Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
    Duvivier, Claudine
    Kolta, Sami
    Assoumou, Lambert
    Ghosn, Jade
    Rozenberg, Sylvie
    Murphy, Robert L.
    Katlama, Christine
    Costagliola, Dominique
    [J]. AIDS, 2009, 23 (07) : 817 - 824
  • [7] A Randomized, Open-Label Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor-Sparing Regimen in Antiretroviral-Naive HIV-Infected Patients
    Harris, Marianne
    Cote, Helene
    Ochoa, Claudia
    Allavena, Clotilde
    Negredo, Eugenia
    Thorne, Anona
    Cahn, Pedro
    Zala, Carlos
    Raffi, Francois
    Clotet, Bonaventura
    Singer, Joel
    Montaner, Julio
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (03) : 335 - 337
  • [8] Safety and Efficacy of GSK2248761, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-1-Infected Subjects
    Zala, Carlos
    St Clair, Marty
    Dudas, Kathleen
    Kim, Joseph
    Lou, Yu
    White, Scott
    Piscitelli, Steve
    Dumont, Etienne
    Pietropaolo, Keith
    Zhou, Xiao-Jian
    Mayers, Douglas
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2570 - 2575
  • [9] TREATMENT PATTERNS AND DRUG TREATMENT COSTS ASSOCIATED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED ANTIRETROVIRAL THERAPY IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS
    Diels, J.
    Langham, S.
    Nuyts, G.
    Adriaenssen, I
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A116 - A117
  • [10] Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART: Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
    Cuzin, Lise
    Allavena, Clotilde
    Morlat, Philippe
    Dellamonica, Pierre
    [J]. AIDS REVIEWS, 2008, 10 (04) : 205 - 211
12345